Literature DB >> 20100132

Correlation between anti-survivin antibody and survivin mRNA expression in head and neck cancer patients.

Naoki Uemura1, Satoru Kodama, Nozomi Nomi, Tomoyo Okamoto, Masashi Suzuki.   

Abstract

CONCLUSIONS: Survivin may act as a major cancer antigen in head and neck cancer, and the present study revealed a link between systemic anti-survivin antibody responses and survivin expression in cancer tissues in patients with head and neck cancer.
OBJECTIVES: Survivin is highly expressed in cancer cells, but is expressed at low levels or not at all in normal tissues. Little is known about the relationship between survivin expression and antibody responses to survivin in patients with head and neck cancer.
METHODS: Anti-survivin antibody responses in sera of head and neck cancer patients were investigated by enzyme-linked immunosorbent assay. The expression of survivin mRNA in the cancer tissues from larynx and hypopharynx was examined by quantitative RT-PCR.
RESULTS: Sera from 42 of 55 patients (76.4%) were positive for anti-survivin. High levels of anti-survivin were detected in patients in the advanced stage of disease. Most cancer tissues, but not normal adjacent tissues, expressed survivin mRNA, and a significant correlation between the levels of anti-survivin antibody in the serum and survivin mRNA in cancer tissues was detected.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100132     DOI: 10.3109/00016480903555416

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma.

Authors:  Yukie Hosono; Maki Goto; Daisuke Kobayashi; Kageaki Kuribayashi; Maki Tanaka; Naoki Watanabe
Journal:  Mol Clin Oncol       Date:  2015-02-06

2.  NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.

Authors:  Zhenjiang Liu; Thomas Poiret; Oscar Persson; Qingda Meng; Lalit Rane; Jiri Bartek; Julia Karbach; Hans-Michael Altmannsberger; Christopher Illies; Xiaohua Luo; Inti Harvey-Peredo; Elke Jäger; Ernest Dodoo; Markus Maeurer
Journal:  Cancer Immunol Immunother       Date:  2017-10-20       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.